Raymond James & Associates Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$144.95 - $152.29 $3.56 Million - $3.74 Million	-24,559 Reduced 67.05%	12,070 $1.83 Million
Q2 2022 Aug 12, 2022	SELL	$83.14 - $145.99 $186,067 - $326,725	-2,238 Reduced 5.76%	36,629 $5.34 Million
Q1 2022 May 11, 2022	BUY	$110.08 - $142.92 $238,543 - $309,707	2,167 Added 5.9%	38,867 $4.61 Million
Q4 2021 Feb 08, 2022	BUY	$99.73 - $148.48 $1.69 Million - $2.52 Million	16,995 Added 86.25%	36,700 $5.06 Million
Q3 2021 Nov 02, 2021	SELL	$98.85 - $138.91 $11,071 - $15,557	-112 Reduced 0.57%	19,705 $2.74 Million
Q2 2021 Aug 11, 2021	BUY	$65.78 - $105.02 $76,173 - $121,613	1,158 Added 6.21%	19,817 $1.92 Million
Q1 2021 May 14, 2021	BUY	$64.07 - $91.75 $442,531 - $633,717	6,907 Added 58.77%	18,659 $1.28 Million
Q4 2020 Feb 12, 2021	SELL	$65.07 - $98.24 $23,685 - $35,759	-364 Reduced 3.0%	11,752 $1.01 Million
Q3 2020 Nov 04, 2020	BUY	$59.04 - $77.95 $52,191 - $68,907	884 Added 7.87%	12,116 $788,000
Q2 2020 Jul 28, 2020	SELL	$29.01 - $74.23 $2,233 - $5,715	-77 Reduced 0.68%	11,232 $821,000
Q1 2020 Apr 21, 2020	BUY	$27.51 - $57.29 $52,764 - $109,882	1,918 Added 20.42%	11,309 $385,000
Q4 2019 Feb 12, 2020	SELL	$40.86 - $57.65 $174,594 - $246,338	-4,273 Reduced 31.27%	9,391 $511,000
Q3 2019 Nov 07, 2019	SELL	$37.38 - $49.47 $7,438 - $9,844	-199 Reduced 1.44%	13,664 $570,000
Q2 2019 Aug 06, 2019	SELL	$39.79 - $67.01 $135,126 - $227,565	-3,396 Reduced 19.68%	13,863 $607,000
Q1 2019 May 06, 2019	BUY	$34.52 - $53.29 $5,108 - $7,886	148 Added 0.86%	17,259 $888,000
Q4 2018 Feb 11, 2019	SELL	$29.75 - $42.9 $7,110 - $10,253	-239 Reduced 1.38%	17,111 $633,000
Q3 2018 Nov 14, 2018	SELL	$32.79 - $43.0 $7,279 - $9,546	-222 Reduced 1.26%	17,350 $651,000
Q2 2018 Aug 14, 2018	SELL	$23.62 - $42.29 $755 - $1,353	-32 Reduced 0.18%	17,572 $694,000
Q1 2018 May 14, 2018	BUY	$22.49 - $34.56 $24,626 - $37,843	1,095 Added 6.63%	17,604 $453,000
Q4 2017 Feb 14, 2018	BUY	$20.44 - $35.56 $15,493 - $26,954	758 Added 4.81%	16,509 $445,000
Q3 2017 Nov 13, 2017	BUY	$23.54 - $38.21 $965 - $1,566	41 Added 0.26%	15,751 $589,000
Q2 2017 Aug 14, 2017	BUY	N/A	15,710	15,710 $393,000

Others Institutions Holding BHVN

# of Institutions

Shares Held

785K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account